CAT

925.54

+3.35%↑

300.73

+1.36%↑

GEV.US

1,071.94

+3.08%↑

RTX

178.67

+1.53%↑

238.11

+0.24%↑

CAT

925.54

+3.35%↑

300.73

+1.36%↑

GEV.US

1,071.94

+3.08%↑

RTX

178.67

+1.53%↑

238.11

+0.24%↑

CAT

925.54

+3.35%↑

300.73

+1.36%↑

GEV.US

1,071.94

+3.08%↑

RTX

178.67

+1.53%↑

238.11

+0.24%↑

CAT

925.54

+3.35%↑

300.73

+1.36%↑

GEV.US

1,071.94

+3.08%↑

RTX

178.67

+1.53%↑

238.11

+0.24%↑

CAT

925.54

+3.35%↑

300.73

+1.36%↑

GEV.US

1,071.94

+3.08%↑

RTX

178.67

+1.53%↑

238.11

+0.24%↑

Home・Listă Acțiuni・Ocugen Inc

Ocugen Inc

Închisă

1.47 -2.65

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.45

Maxim

1.5899999999999999

Indicatori cheie
By Trading Economics
Venit	2.3M -18M
Vânzări	-1.9M -193K
Marjă de profit	9,174.093
Angajați	116
EBITDA	1.5M -16M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+666.23% upside

Dividende
By Dow Jones
Următoarele câștiguri	31 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-8.7M 626M
Deschiderea anterioară	4.12
Închiderea anterioară	1.47

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

0.6818 / 0.74 Suport & Rezistență

Ocugen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 mai 2026, 23:47 UTC

Market Talk

Gold Falls on Renewed Inflation Concerns -- Market Talk

10 mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10 mai 2026, 23:38 UTC

Market Talk

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10 mai 2026, 23:14 UTC

Market Talk

Australia's Political Map Continues to Be Redrawn -- Market Talk

10 mai 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

Elevra Lithium: Expects Deal to Close in 1Q FY27

10 mai 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10 mai 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10 mai 2026, 10:21 UTC

Câștiguri

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9 mai 2026, 06:05 UTC

Câștiguri

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 mai 2026, 23:55 UTC

Câștiguri

Review & Preview: Still Going Strong -- Barrons.com

8 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 mai 2026, 20:49 UTC

Câștiguri

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 mai 2026, 20:25 UTC

Câștiguri

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mai 2026, 19:43 UTC

Câștiguri

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 mai 2026, 19:43 UTC

Câștiguri

Cencosud 1Q Net $115M

8 mai 2026, 19:20 UTC

Market Talk

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 mai 2026, 19:18 UTC

Câștiguri

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 mai 2026, 19:16 UTC

Câștiguri

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mai 2026, 19:08 UTC

Câștiguri

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mai 2026, 19:05 UTC

Câștiguri

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 mai 2026, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 mai 2026, 18:51 UTC

Câștiguri

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 mai 2026, 18:49 UTC

Câștiguri

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mai 2026, 18:41 UTC

Câștiguri

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 mai 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 mai 2026, 17:14 UTC

Câștiguri

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 mai 2026, 17:04 UTC

Market Talk

Zcash Caps Off Parabolic Week -- Market Talk

8 mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Comparație

Modificare preț

Ocugen Inc Așteptări

Obiectiv de preț

By TipRanks

666.23% sus

Prognoză pe 12 luni

Medie 11.57 USD 666.23%

Maxim 22 USD

Minim 7 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOcugen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 7 analiști care au acordat evaluări ale acțiunilor Ocugen Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

0.6818 / 0.74Suport & Rezistență

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.